NEWS
Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World
Windtree Therapeutics (NASDAQ: WINT) has completed national phase patent filings for its istaroxime formulation across major global markets, including the United States, Germany, France, Italy, Japan, and China. The patent, numbered PCT/US2023/018998 and application No. 18/858,086, is titled 'ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF PRE-CARDIOGEN1C SHOCK AND CARDIOGENIC SHOCK'. This strategic move aims to strengthen the company's intellectual property position for istaroxime in treating cardiogenic shock patients.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Teo knows : Thanks Jag